Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

被引:24
作者
Gordon, Sarah W. [1 ,4 ]
McGuire, William P., III [1 ,4 ]
Shafer, Danielle A. [1 ,4 ]
Sterling, Richard K. [5 ]
Lee, Hannah M. [5 ]
Matherly, Scott C. [5 ]
Roberts, John D. [6 ]
Bose, Prithviraj [7 ]
Tombes, Mary B. [1 ,4 ]
Shrader, E. Ellen [1 ]
Ryan, Alison A. [1 ,4 ]
Kmieciak, Maciej [1 ]
Tri Nguyen [1 ]
Deng, Xiaoyan [2 ]
Bandyopadhyay, Dipankar [2 ]
Dent, Paul [1 ,3 ]
Poklepovic, Andrew S. [1 ,4 ]
机构
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, Richmond, VA USA
[2] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA
[3] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA USA
[4] Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Richmond, VA USA
[5] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA
[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2019年 / 42卷 / 08期
基金
美国国家卫生研究院;
关键词
sorafenib; vorinostat; hepatocellular carcinoma; HISTONE DEACETYLASE INHIBITORS; RESPONSE EVALUATION CRITERIA; SOLID TUMORS; RAF/MEK/ERK PATHWAY; ANGIOGENESIS; APOPTOSIS; INDUCTION; TARGETS; RECIST; CELLS;
D O I
10.1097/COC.0000000000000567
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma. Materials and Methods: Patients received vorinostat (200 to 400 mg by mouth once daily, 5 of 7 d) and sorafenib at standard or reduced doses (400 mg [cohort A] or 200 mg [cohort B] by mouth twice daily). Patients who received 14 days of vorinostat in cycle 1 were evaluable for dose-limiting toxicity (DLT). Results: Sixteen patients were treated. Thirteen patients were evaluable for response. Three patients experienced DLTs, 2 in cohort A (grade [gr] 3 hypokalemia; gr 3 maculopapular rash) and 1 in cohort B (gr 3 hepatic failure; gr 3 hypophosphatemia; gr 4 thrombocytopenia). Eleven patients required dose reductions or omissions for non-DLTtoxicity. Ten patients (77%) had stable disease (SD). The median treatment duration was 4.7 months for response-evaluable patients. One patient with SD was on treatment for 29.9 months, and another patient, also with SD, was on treatment for 18.7 months. Another patient electively stopped therapy after 15 months and remains without evidence of progression 3 years later. Conclusions: Although some patients had durable disease control, the addition of vorinostat to sorafenib led to toxicities in most patients, requiring dose modifications that prevented determination of the recommended phase 2 dose. The combination is not recommended for further exploration with this vorinostat schedule in this patient population.
引用
收藏
页码:649 / 654
页数:6
相关论文
共 50 条
  • [41] A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
    Ciuleanu, T.
    Bazin, I.
    Lungulescu, D.
    Miron, L.
    Bondarenko, I.
    Deptala, A.
    Rodriguez-Torres, M.
    Giantonio, B.
    Fox, N. L.
    Wissel, P.
    Egger, J.
    Ding, M.
    Kalyani, R. N.
    Humphreys, R.
    Gribbin, M.
    Sun, W.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 680 - 687
  • [42] Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
    Morimoto, Manabu
    Numata, Kazushi
    Kondo, Masaaki
    Hidaka, Hisashi
    Takada, Juichi
    Shibuya, Akitaka
    Kobayashi, Satoshi
    Ohkawa, Shinichi
    Okuse, Chiaki
    Morita, Satoshi
    Taguri, Masataka
    Tanaka, Katsuaki
    HEPATOLOGY RESEARCH, 2011, 41 (04) : 296 - 302
  • [43] Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma
    Chen, Shang-Wen
    Lin, Li-Ching
    Kuo, Yu-Cheng
    Liang, Ji-An
    Kuo, Chia-Chun
    Chiou, Jeng-Fong
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (05): : 1041 - 1047
  • [44] Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
    Ikeda, Kenji
    Kudo, Masatoshi
    Kawazoe, Seiji
    Osaki, Yukio
    Ikeda, Masafumi
    Okusaka, Takuji
    Tamai, Toshiyuki
    Suzuki, Takuya
    Hisai, Takashi
    Hayato, Seiichi
    Okita, Kiwamu
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) : 512 - 519
  • [45] Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma
    Zhu, Andrew X.
    Abrams, Thomas A.
    Miksad, Rebecca
    Blaszkowsky, Lawrence S.
    Meyerhardt, Jeffrey A.
    Zheng, Hui
    Muzikansky, Alona
    Clark, Jeffrey W.
    Kwak, Eunice L.
    Schrag, Deborah
    Jors, Kathryn R.
    Fuchs, Charles S.
    Iafrate, A. John
    Borger, Darrell R.
    Ryan, David P.
    CANCER, 2011, 117 (22) : 5094 - 5102
  • [46] Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
    Campos, Marta
    Candelaria, Isabel
    Papanikolaou, Nickolas
    Simao, Adelia
    Ferreira, Carlos
    Manikis, Georgios C.
    Caseiro-Alves, Filipe
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2019, 26 (04) : 260 - 267
  • [47] Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study
    Bitzer, Michael
    Horger, Marius
    Giannini, Edoardo G.
    Ganten, Tom M.
    Woerns, Marcus A.
    Siveke, Jens T.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    Wege, Henning
    Zagonel, Vittorina
    Cillo, Umberto
    Trevisani, Franco
    Santoro, Armando
    Montesarchio, Vincenzo
    Malek, Nisar P.
    Holzapfel, Julia
    Herz, Thomas
    Ammendola, Astrid S.
    Pegoraro, Stefano
    Hauns, Bernhard
    Mais, Anna
    Lauer, Ulrich M.
    Henning, Stefan W.
    Hentsch, Bernd
    JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 280 - 288
  • [48] Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
    Nakano, Masahito
    Tanaka, Masatoshi
    Kuromatsu, Ryoko
    Nagamatsu, Hiroaki
    Satani, Manabu
    Niizeki, Takashi
    Okamura, Shusuke
    Iwamoto, Hideki
    Shimose, Shigeo
    Shirono, Tomotake
    Noda, Yu
    Koga, Hironori
    Torimura, Takuji
    ONCOTARGET, 2016, 7 (39) : 64400 - 64409
  • [49] Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
    Dufour, Jean-Francois
    Hoppe, Hanno
    Heim, Markus H.
    Helbling, Beat
    Maurhofer, Olivier
    Szucs-Farkas, Zsolt
    Kickuth, Ralph
    Borner, Markus
    Candinas, Daniel
    Saar, Bettina
    ONCOLOGIST, 2010, 15 (11) : 1198 - 1204
  • [50] Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
    Nishikawa, Hiroki
    Osaki, Yukio
    Iguchi, Eriko
    Takeda, Haruhiko
    Nakajima, Jun
    Matsuda, Fumihiro
    Sakamoto, Azusa
    Henmi, Shinichiro
    Hatamaru, Keiichi
    Sarro, Sumio
    Nasu, Akihiro
    Kita, Ryuichi
    Kimura, Toru
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (03) : 381 - 386